Based on MPM datasets from The Cancer Genome Atlas (TCGA) (n = 86) and the Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT, targeted screen) (n = 61), the percentages of patients with combined alterations in CDKN2A/B and NF2 were 8% (n = 7) and 5% (n = 3), respectively, which also showed a significant association with poor survival in MPM patients99. The gene discussed is NF2; the disease is cancer.